[KSCI] Korea Science Citation Index Service

http://dx.doi.org/10.3831/KPI.2020.23.001

Nicotine Addiction: Neurobiology and Mechanism

Tiwari, Raj Kumar (Columbia Institute of Pharmacy)
Sharma, Vikas (Columbia Institute of Pharmacy)
Pandey, Ravindra Kumar (Columbia Institute of Pharmacy)
Shukla, Shiv Shankar (Columbia Institute of Pharmacy)

Publication Information

Journal of Pharmacopuncture / v.23, no.1, 2020 , pp. 1-7 More about this Journal

Abstract

Nicotine, primary component of tobaco produces craving and withdrawal effect both in humans and animals. Nicotine shows a close resemblance to other addictive drugs in molecular, neuroanatomical and pharmacological, particularly the drugs which enhances the cognitive functions. Nicotine mainly shows its action through specific nicotinic acetylcholine receptors located in brain. It stimulates presynaptic acetylcholine receptors thereby enhancing Ach release and metabolism. Dopaminergic system is also stimulated by it, thus increasing the concentration of dopamine in nuclear accumbens. This property of nicotine according to various researchers is responsible for reinforcing behavioral change and dependence of nicotine. Various researchers have also depicted that some non dopaminergic systems are also involved for rewarding effect of nicotinic withdrawal. Neurological systems such as GABAergic, serotonergic, noradrenergic, and brain stem cholinergic may also be involved to mediate the actions of nicotine. Further, the neurobiological pathway to nicotine dependence might perhaps be appropriate to the attachment of nicotine to nicotinic acetylcholine receptors, peruse by stimulation of dopaminergic system and activation of general pharmacological changes that might be responsible for nicotine addiction. It is also suggested that MAO A and B both are restrained by nicotine. This enzyme helps in degradation dopamine, which is mainly responsible for nicotinic actions and dependence. Various questions remain uninsurable to nicotine mechanism and require more research. Also, various genetic methods united with modern instrumental analysis might result for more authentic information for nicotine addiction.

Keywords

Nicotine; dopaminergic system; GABAergic; withdrawal; acetylcholine; MAO;

Citations & Related Records

Reference

1	Kollins SH, McClernon FJ, Fuemmeler BF. Association between smoking and attention-deficit/hyperactivity disorder symptoms in a population-based sample of young adults. Arch Gen Psychiatry. 2005;62:1142-7. DOI
2	Heishman SJ, Kleykamp BA, Singleton EG. Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology. 2010;210:453-69. DOI
3	Jain R, Varma S, Mohan D. Effects of selective dopaminergic drugs in nicotine tolerant rats. Drug Alcohol Depend. 2001;63:72.
4	Hopkins TJ, Rupprecht LE, Hayes MR, Blendy JA, Schmidt HD. Galantamine, an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic acetylcholine receptors, attenuates nicotine taking and seeking in rats. Neuropsychopharmacology. 2012;37:2310-21. DOI
5	Kushner HI. Toward a cultural biology of addiction. BioSocieties. 2010;5(1):8-24. DOI
6	Addicott MA, et al. Smoking withdrawal is associated with increases in brain activation during decision making and reward anticipation: a preliminary study. Psychopharmacology (Berl). 2012;219(2):563-73 DOI
7	Gotti C, Clementi F, Fornari A, Gaimarri A, Guiducci S, Manfredi I, et al. Structural and functional diversity of native brain neuronal nicotinic receptors. Biochem Pharmacol. 2009;78:703-11. DOI
8	Satoshi I. Brain reward circuitry beyond the mesolimbic dopamine system: A neurobiological theory. Neurosci Biobehav Rev. 2010;35(2): 129-50. DOI
9	Christopher C Lapish, Sven K, Daniel D, Antonieta L, Jeremy K Seamans. The ability of the mesocortical dopamine system to operate in distinct temporal modes. Psychopharmacology. 2007;191(3): 609-25. DOI
10	Centers for Disease Control and Prevention (US); National Center for Chronic Disease Prevention and Health Promotion (US); Office on Smoking and Health (US). How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Atlanta (GA): Centers for Disease Control and Prevention (US); 2010. 4, Nicotine Addiction: Past and Present.
11	Christian L, Mark AU. The Mechanistic Classification of Addictive Drugs. PLoS Med. 2006;3(11):e437. DOI
12	Bryon AD. Neurobiological Processes in Drug Reward and Addiction. Harv Rev Psychiatry. 2004;12(6):305-20. DOI
13	Alfred JR, Eric JN. Transcriptional and Epigenetic Mechanisms of Addiction. Nat Rev Neurosci. 2011;12(11):623-37. DOI
14	Hugo JO, David CG, Ernestina HG, Gerardo BM. The Role of Dopamine and Its Dysfunction as a Consequence of Oxidative Stress. Oxid Med Cell Longev. 2016;2016: 9730467.
15	Buchta WC, Riegel AC. Chronic cocaine disrupts mesocortical learning mechanisms. Brain Research. 2015;631-5. DOI
16	Salas R, Cook KD, Bassetto L, De Biasi M. The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for nicotine-induced seizures and hypolocomotion in mice. Neuropharmacology. 2004; 47(3):401-7. DOI
17	Deutch AY, Roth RH. The determinants of stress-induced activation of the prefrontal cortical dopamine system. Progress in Brain Research. 1990;85:367-403. DOI
18	Schmitt KC, Rothman RB, Reith ME. Nonclassical pharmacology of the dopamine transporter: atypical inhibitors, allosteric modulators, and partial substrates. Journal of Pharmacology and Experimental Therapeutics. 2013;346(1):2-10. DOI
19	Calabresi P, Picconi B, Tozzi A, Di Filippo M. Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends in Neurosciences. 2007;30(5):211-9 DOI
20	Bernard LF, Steven RG. Effects of nicotine in experimental animals and humans: an update on addictive properties. Handb Exp Pharmacol. 2009; (192): 335-67.
21	Neal LB. Pharmacology of Nicotine: Addiction, Smoking-Induced Disease, and Therapeutics. Annu Rev Pharmacol Toxicol. 2009; 49:57-71. DOI
22	Charles RW, Michael JM, Sharon RG. Effectiveness of Nicotinic Agonists as Desensitizers at Presynaptic ${\alpha}4{\beta}2$ - and ${\alpha}4{\alpha}5{\beta}2$ -Nicotinic Acetylcholine Receptors. Nicotine Tob Res. 2014;16(3): 297-305. DOI
23	Arthur L.B, Alexey G.M, Michael SM, Trinh L, Meaghan N, Lidia L, Jennifer S, Catherine AS, Jed ER, Mark AM. Brain Nicotinic Acetylcholine Receptor Availability and Response to Smoking Cessation Treatment A Randomized Trial. JAMA Psychiatry. 2014;71(7):797-805. DOI
24	Rachel EP, Robin AJL. Cellular Events in Nicotine Addiction Semin Cell Dev Biol. 2009;20(4): 418-31. DOI
25	Wang H, Sun X. Desensitized nicotinic receptors in brain. Brain Res Brain Res Rev. 2005;48(3):420-37. DOI
26	Yates SL, Bencherif M, Fluhler EN, Lippiello PM. Up-regulation of nicotinic acetylcholine receptors following chronic exposure of rats to mainstream cigarette smoke or alpha 4 beta 2 receptors to nicotine. Biochem Pharmacol. 1995;50(12):2001-8. DOI
27	Laura M, Emanuele S, Enrico C. Regulation of GABA release by nicotinic acetylcholine receptors in the neonatal rat hippocampus. J Physiol. 2001;536(Pt 1): 89-100. DOI
28	Nick C, Ortiz BA, Heidi C, O'Neill, Michael J, Marks, et al. Varenicline Blocks ${\beta}2$ -nAChR-Mediated Response and Activates ${\beta}4$ -nAChR-Mediated Responses in Mice In Vivo Nicotine. Tob Res. 2012;14(6): 711-9. DOI
29	Goshman LM. Clinical Toxicology of Commercial Products. Journal of Pharmaceutical Sciences. 1985;74:1139-55. DOI
30	Tiwari RK, Shukla SS, Roy A, Satapathy T, Pandey R. Role of Serotonin in Relapse to Nicotine addiction: An Overview. Advance Research in Pharmaceuticals & Biologicals. 2012;2(II):157-66.
31	Cunha OT, Rego AC, Oliveira CR. Cellular and molecular mechanisms involved in the neurotoxicity of opioid and psychostimulant drugs. Brain Res Rev. 2008;58(1):192-208. DOI
32	Zhu PJ, Chiappinelli VA. Nicotine modulates evoked GABAergic transmission in the brain. J Neurophysiol. 1999;82:3041-5. DOI
33	Perkins K, Stitzer M, Lerman C. Medication screening for smoking cessation: a proposal for new methodologies. Psychopharmacology. 2006;184(3-4):628-36. DOI
34	Hurst R, Rollema H, Bertrand D. Nicotinic acetylcholine receptors: from basic science to therapeutics. Pharmacol Ther. 2013;137:22-54. DOI
35	Di Chiara G. Role of dopamine in the behavioural actions of nicotine related to addiction. European journal of pharmacology. 2000;393(1):295-314-344. DOI
36	Bardo MT, Green TA, Crooks PA, Dwoskin LP. Nornicotine is self-administered intravenously by rats. Psychopharmacology. 1999;146(3):290-6. DOI
37	Jin HP, Soo K, Areum D, Ji HK, Ah JK. Symptomatic bradycardia due to nicotine intoxication. Rev Bras Ter Intensiva. 2018; 30(1):121-6. DOI
38	Danyan M, Keith G, Daniel S, Mc Gehee. Nicotine potentiation of excitatory inputs to VTA dopamine neurons J Neurosci. 2011; 31(18): 6710-20. DOI
39	Pidoplichko VI, DeBiasi M, Williams JT, Dani JA. Nicotine activates and desensitizes midbrain dopamine neurons. Nature. 1997;390(6658):401-4. DOI
40	Jain R, Mukherjee K. Biological basis of nicotine addiction. Indian Journal of Pharmacology. 2003;35:281-9.
41	Jiloha RC. Biological basis of tobacco addiction: Implications for smoking-cessation treatment. Indian J Psychiatry. 2010;52(4):301-7 DOI
42	Galindo CL, Hernandez LS, Galarraga E, Tapia D, Bargas J, Garduno J, et al. Serotoninergic dorsal raphe neurons possess functional postsynaptic nicotinic acetylcholine receptors. Synapse. 2008; 62(8):601-15. DOI
43	Munir GK, Thomas JG. Nicotine Modulation of Fear Memories and Anxiety: Implications for Learning and Anxiety Disorders. Biochem Pharmacol. 2015; 97(4):498-511. DOI
44	Yue X, Edward FD. Tobacco/Nicotine and Endogenous Brain Opioids Prog Neuropsychopharmacol. Biol Psychiatry. 2008;32(5): 1131-8.
45	Meaghan C, Creed NRN, Kelly RT. VTA GABA neurons modulate specific learning behaviors through the control of dopamine and cholinergic systems. Front Behav Neurosci. 2014;8:8. DOI
46	George EB, Alexander I, Valentina EM. Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson's disease. Front Aging Neuro-sci. 2014; 6: 340.
47	Bierut LJ, Stitzel JA, Wang JC, Hinrichs AL, Grucza RA, Xuei X, et al. 2008. Variants in nicotinic receptors and risk for nicotine dependence. Am J Psychiatry. 165:1163-71. DOI
48	Joanna SF, Nora DV, Gene JW, Naomi P, Jean L, Colleen S, et al. Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci U S A. 1996;93(24):14065-9. DOI
49	Tyndale RF, Pianezza ML, Sellers EM. A common genetic defect in nicotine metabolism decreases risk for dependence and lowers cigarette consumption. Nicotine Tob Res. 1999; 1(Suppl 2):S63-7.
50	Julie AT, Jeffrey AH, Dedra B, Barbara VH, Patricia NH, Rachel FT. Variation in CYP2A6 and nicotine metabolism among two American Indian tribal groups differing in smoking patterns and risk for tobacco-related cancer. Pharmacogenet Genomics. 2017; 27(5):169-78. DOI
51	Johnstone EC, Yudkin PL, Hey K, et al. Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics. 2004;14(2):83-90. DOI
52	Neal LB. Pharmacology of Nicotine: Addiction, Smoking-Induced Disease, and Therapeutics. Annu Rev Pharmacol Toxicol. 2009;49:57-71. DOI